<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436656</url>
  </required_header>
  <id_info>
    <org_study_id>CLGX818X2101</org_study_id>
    <secondary_id>2011-000556-42</secondary_id>
    <nct_id>NCT01436656</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose
      (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily
      and/or every-other-day), a RAF kinase inhibitor. Patients with locally advanced or metastatic
      melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase)
      and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the
      expansion phase) will be enrolled. The study consists of a dose escalation part were cohorts
      of patients will receive escalating oral doses of LGX818, followed by a safety dose expansion
      part were patients will be treated with oral dose of LGX818 given at the MTD or RP2D.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>Approximately every 8 weeks (up to 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and nature of Adverse events and clinical activity</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of LGX818</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>LGX818 Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response per RECIST</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>This includes duration of response, time to response, progression free survival and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline molecular status</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Baseline molecular status (mutation/ amplification/ expression) in tumor tissue of potential predictive markers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Melanoma and Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LGX818 - Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 - Dose Expansion at MTD or RP2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGX818</intervention_name>
    <arm_group_label>LGX818 - Dose escalation</arm_group_label>
    <arm_group_label>LGX818 - Dose Expansion at MTD or RP2D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For the dose escalation phase:

          1. Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage
             IIIB to IV per American Joint Committee on Cancer [AJCC]). For the dose expansion
             phase: (i) Histologically confirmed diagnosis of locally advanced or metastatic
             melanoma (stage IIIB to IV per American Joint Committee on Cancer [AJCC]), or (ii)
             confirmed diagnosis and non-resectable advanced metastatic colorectal cancer (mCRC)
             for which no further effective standard therapy exists.

          2. Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation.

          3. Evidence of measurable disease

        Exclusion Criteria:

          1. Previous therapy with a MEK inhibitor.

          2. Symptomatic or untreated leptomeningeal disease.

          3. Symptomatic or untreated brain metastasis.Patients previously treated for these
             conditions that are asymptomatic in the absence of corticosteroid therapy are allowed
             to enroll. Brain metastasis must be stable with verification by imaging.

          4. Known acute or chronic pancreatitis.

          5. Clinically significant cardiac disease

          6. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral LGX818

          7. Previous or concurrent malignancy. Exceptions to this exclusion criteria include:
             adequately treated basal cell or squamous cell skin cancer; in situ carcinoma of the
             cervix, treated curatively and without evidence of recurrence for at least 3 years
             prior to study entry; or other solid tumor treated curatively, and without evidence of
             recurrence for at least 3 years prior to study entry.

          8. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt; 5 mIU/mL).

          9. History of thromboembolic or cerebrovascular events within the last 6 months

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Array BioPharma</last_name>
    <role>Study Director</role>
    <affiliation>303-381-6604</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute Moffitt SC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Mass General 2</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Array BioPharma Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAF mutant,</keyword>
  <keyword>BRAF mutated,</keyword>
  <keyword>melanoma,</keyword>
  <keyword>metastatic,</keyword>
  <keyword>advanced,</keyword>
  <keyword>RAF kinase inhibitor</keyword>
  <keyword>BRAF V600 mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

